HIV

HIV prevention and treatment recommendations for adults can be found with new AIDSinfo app.

One-third of HIV-infected Americans are co-infected with hepatitis C virus (HCV), and 75% to 90% of HIV-positive intravenous drug users are co-infected.

Researchers call for regular HIV testing and pre-exposure prophylaxis combined with early treatment.

Few state minor-consent laws authorize participation in clinical trials and therapies.

Consistent PrEP use can lower the risk of HIV infection by 92% among those at high risk for transmission.

Consistent PrEP use can lower the risk of HIV infection by 92% among those at high risk for transmission.

Several factors influence survival among patients with both HIV and Hodgkin’s lymphoma.

Emtricitabine-tenofovir disoproxil fumarate found to be comparable in safety to PrEP.

Study finds many silver plans have higher out-of-pocket costs for most the commonly prescribed HIV treatments.

Program’s ability to address adverse effects found to improve outcomes.

The FDA has lifted the indefinite deferral of blood donation for men who have sex with men.

Researchers achieve promising first step in new HIV treatment approach.

Alpha therapy shows promise in selectively killing infected cells from the central nervous system.

Most read HIV articles from the past year.

Several barriers prevent many health care providers from prescribing pre-exposure prophylaxis to patients at high risk for HIV.

Taking drug around periods of sexual activity lowers transmission rates.

An HIV pre-exposure prophylaxis program piloted at a pharmacy in Seattle shows promising results for patients.

Pharmacists can help patients with HIV through refill reminders, pillboxes, or delivering medications to homes or workplaces.

Taking antiretroviral therapy exactly as prescribed is not only essential for lowering the amount of HIV in an infected individual, but also critical for reducing the risk of transmission.

Researchers find link between HIV infection and stroke.

Novel small ubiquitin-like modifier protease inhibitor drug class shows promise.

In June of 1981 an unspeakable new disease entered the public consciousness in the United States and it did so quickly and unexpectedly, leaving illness, tragedy, and death in its wake.

New treatments for HIV infection are desperately needed.

New research may allow for HIV to be attacked at its core.

Statins show promise to reduce liver disease incidence in coinfected patients.